急进性肾小球肾炎患者的临床治疗分析

Clinical Treatment Analysis of Patients with Rapidly Progressive Glomerulonephritis

目的探究急进性肾小球肾炎患者的临床治疗方法与效果。方法此次研究选取2017年2月至2018年2月在我院纳入治疗的84例急进性肾小球肾炎患者,按随机数字表法将其分成两个不同的组别,每组平均为42例;其中,对照组患者采取常规药物治疗,观察组患者采取血浆置换疗法治疗,对两组临床治疗效果进行比较分析。结果①观察组治疗总有效率为90.48%,显著高于对照组的61.90%(P<0.05)。②治疗前,观察组与对照组血清抗肾小球基底膜抗体(抗-GBM)、抗髓过氧化物酶抗体(ANCA-MPO)两项指标水平比较无差异(P>0.05);治疗后,两组指标水平皆有下降,但观察组下降幅度显著优于对照组(P<0.05)。③观察组并发症总发生率为4.76%,显著低于对照组的21.43%(P<0.05)。④观察组复发率为7.14%,显著低于对照组的23.81%(P<0.05)。结论运用血浆置换法治疗急进性肾小球肾炎患者,临床效果显著,且安全高效。

Objective Explore the clinical treatment methods and effects of patients with rapidly progressive glomerulonephritis.Methods This study selected 84 patients with rapidly progressive glomerulonephritis who were admitted to our hospital from February 2017 to February 2018,and divided them into two different groups according to the random number table method,each with an average of 42 cases;among them,patients in the control group were treated with conventional drugs,and patients in the observation group were treated with plasma exchange therapy.The clinical treatment effects of the two groups were compared and analyzed.Results(1)The total effective rate of treatment in the observation group was 90.48%,which was significantly higher than 61.90%in the control group(P<0.05).(2)Before treatment,there was no difference in serum anti-glomerular basement membrane antibody(anti-GBM)and anti-myeloperoxidase antibody(ANCA-MPO)levels between the observation group and the control group(P>0.05);after treatment,the index levels of the two groups both declined,but the decline of the observation group was significantly better than that of the control group(P<0.05).(3)The total incidence of complications in the observation group was 4.76%,which was significantly lower than the 21.43%in the control group(P<0.05).(4)The recurrence rate of the observation group was 7.14%,which was significantly lower than the 23.81%of the control group(P<0.05).Conclusion The use of plasma exchange method to treat patients with rapidly progressive glomerulonephritis has significant clinical effects,and is safe and efficient.